[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche ’s Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma
Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of non-Hodgkin lymphoma in the USPOLARIX trial showed thePolivy combination reduced the risk of disease progression, relapse or death by 27% compared to the standard of care, R-CHOP, with a comparable safety profileFirst-line treatment withPolivy plus R-CHP has the potential to reduce the burden on patients and healthcare systems, associated with disease progressionBasel, 19 April 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that t...
Source: Roche Media News - April 19, 2023 Category: Pharmaceuticals Source Type: news
Bariatric Surgery Improves Many Diabetes Complications
MONDAY, April 17, 2023 -- For individuals with class II/III obesity, bariatric surgery improves peripheral neuropathy (PN), according to a study published online March 14 in Diabetologia.
Evan L. Reynolds, Ph.D., from the University of Michigan in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 17, 2023 Category: Pharmaceuticals Source Type: news
Weight-Loss Surgery Might Reverse the Nerve Damage From Diabetes
Two years after weight loss surgery, researches found patients had improvements in peripheral neuropathay aTwo years after weight loss surgery, researches found patients had improvements in peripheral neuropathy as well as high blood sugar (glucose) levels and levels of certain lipids (fats).s well as high blood sugar (glucose) levels and levels of certain lipids (fats). (Source: WebMD Health)
Source: WebMD Health - April 13, 2023 Category: Consumer Health News Source Type: news
The association of peripheral neuropathy detected by monofilament testing with risk of falls and fractures in older adults - Hicks CW, Wang D, Daya N, Juraschek SP, Matsushita K, Windham BG, Selvin E.
BACKGROUND: In persons with diabetes, annual screening for peripheral neuropathy (PN) using monofilament testing is the standard of care. However, PN detected by monofilament testing is common in older adults, even in the absence of diabetes. We aimed to a... (Source: SafetyLit)
Source: SafetyLit - March 24, 2023 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
Pain Management
Ms. P is a 72-year-old woman who was admitted for rehabilitation after an above-the-knee amputation for a lower-extremity ulcer that did not heal due to associated arterial insufficiency. Her past medical history includes a cerebral vascular event and left hemiparesis, diabetes controlled by diet and oral medication, hypertension, peripheral neuropathy, and arterial insufficiency. (Source: Caring for the Ages)
Source: Caring for the Ages - March 1, 2023 Category: Health Management Authors: Barbara Resnick, Paige Hector Tags: Interdisciplinary Team Case Scenario Source Type: news
What is PAN?
Discussion
Vasculitis is an inflammation of the blood vessels. Often, the term implies the arterial vessels, but venous and capillary vessels can be affected. The nomenclature to describe vasculitis and its classification have varied over time. Arterial vessel size is one method and some more common entities include:
Small vessel, mainly
Granulomatous – granulomatosis with polyangiitis (aka Wegener’s granulomatosis), eosinophilic granulomatosis with polyangiitis (aka Churg Strauss syndrome)
Nongranulomatous – Henoch-Schonlein purpura (HSP), microscopic polyangiitis
Medium vessel, mainly
Childhood sys...
Source: PediatricEducation.org - February 27, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
FDA Clears Spinal Cord Stimulator for Diabetic Neuropathy FDA Clears Spinal Cord Stimulator for Diabetic Neuropathy
The Food and Drug Administration has approved Abbott ' s Proclaim XR spinal cord stimulation system for the treatment of diabetic peripheral neuropathy, the company announced.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 26, 2023 Category: Endocrinology Tags: Neurology & Neurosurgery News Alert Source Type: news
FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy
The new indication for Abbott's Proclaim XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy
Spinal cord stimulation is proven to be more effective than conventional medical management in the treatment ... Devices, Neurology, FDA Abbott, spinal cord stimulation, diabetic peripheral neuropathy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 26, 2023 Category: Pharmaceuticals Source Type: news
FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy
(Source: Abbott.com)
Source: Abbott.com - January 26, 2023 Category: Pharmaceuticals Source Type: news
Antihypertensives and Dementia; Peripheral Neuropathy Marker; Who Can Get Lecanemab?
(MedPage Today) -- New use of antihypertensive medications that stimulated rather than inhibited type 2 and 4 angiotensin II receptors was linked with lower dementia risk. (JAMA Network Open)
Full data about an implanted endovascular brain-computer... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - January 10, 2023 Category: Neurology Source Type: news
Post-acute Sensory Neurological Sequelae in SARS-CoV2 Infection Post-acute Sensory Neurological Sequelae in SARS-CoV2 Infection
This study investigated the incidence and severity of peripheral neuropathy and pain symptoms in patients who tested positive for SARS-CoV-2 infection, both acutely and up to 90 days after testing.Pain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 14, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
What to Know About Diabetes and the Risk of Silent Heart Attacks
At first it seemed like a routine call—something the paramedics had dealt with countless times before. A man in his mid-50s was having a heart attack, and his physician had called for emergency support. But when the paramedics arrived, the physician pulled them aside and told them something peculiar: the man had no cardiovascular symptoms whatsoever.
The man had come to his doctor’s office because he’d woken early the previous morning sweating and with a sharp pain in his left wrist. These symptoms had quickly subsided and he’d gone back to sleep. Later, after going about his day, he’d visited...
Source: TIME: Health - November 4, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate heart health Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Bexion Pharmaceuticals doses first patient in new cancer clinical study
A Northern Kentucky startup developing targeted therapies for cancer has dosed its first patient in a clinical study being held in Cincinnati.
Covington-based Bexion Pharmaceuticals, a clinical-stage biopharma company, said Tuesday it dosed its first adult patient in the new study for BXQ-350, its lead drug candidate.
The study, known as RETRO, will assess the potential for BXQ-350 to reduce the intensity and/or duration of chemotherapy-induced peripheral neuropathy, or CIPN, a common side effect… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - October 19, 2022 Category: Health Management Authors: Liz Engel Source Type: news
